Domainex has announced a collaboration with Sigma-Aldrich that will provide biochemical assays and monoclonal antibodies for the study of proteins involved in the field of epigenetics.
These epigenetic proteins regulate DNA expression and can be critical to cancer and stem-cell biology research.
Funding from the UK government-backed Technology Strategy Board will support this work.
Under the collaboration, Domainex will use its proprietary Combinatorial Domain Hunting (CDH) technology, which enables researchers to clone and express challenging proteins, to produce soluble domains of a number of proteins that have key roles in epigenetics.
Domainex will use those proteins to construct biochemical assays for the target enzymes and Sigma-Aldrich will use the proteins as antigens to raise specific monoclonal antibodies.
The assays and monoclonal antibodies, which will be distributed by Sigma-Aldrich, will be used by researchers to identify the target proteins and allow their function to be characterised and studied in detail.
